At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MANE Veradermics, Inc.
Trading 10-26 12:37:01 EDT
139.46
+0.68
+0.49%
High140.80Low136.67Vol155.59K
Open136.67D1 Closing138.78Amplitude2.98%
Mkt Cap5.83BTradable Cap4.50BTotal Shares41.78M
T/O21.67MT/O Rate0.48%Tradable Shares32.29M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Veradermics Price Target Raised to $204.00/Share from $170.00 by B. Riley Securities
Dow Jones  ·  10-23
Veradermics Price Target Raised to $204.00/Share from $170.00 by B. Riley Securities
B. Riley Raises Price Target on Veradermics to $204 From $170, Keeps Buy Rating
MT Newswires Live  ·  10-22
B. Riley Raises Price Target on Veradermics to $204 From $170, Keeps Buy Rating
Veradermics, Incorporated : B. Riley Raises Target Price to $204 from $170
THOMSON REUTERS  ·  10-22
Veradermics, Incorporated : B. Riley Raises Target Price to $204 from $170
Movement Alert｜Veradermics, Inc. Intraday Rise 5.01% in Regular Trading, Clinical Progress and Cash Position Remain Supportive
Market Focus  ·  10-21
Movement Alert｜Veradermics, Inc. Intraday Rise 5.01% in Regular Trading, Clinical Progress and Cash Position Remain Supportive
Veradermics Presents Positive Vdphl01 Data from Two Male Pattern Hair Loss Trials
Reuters  ·  10-21
Veradermics Presents Positive Vdphl01 Data from Two Male Pattern Hair Loss Trials
Movement Alert｜Veradermics, Inc. Intraday Rise 5.26% in Regular Trading, clinical progress and cash reserves remain supportive
Market Focus  ·  10-20
Movement Alert｜Veradermics, Inc. Intraday Rise 5.26% in Regular Trading, clinical progress and cash reserves remain supportive
Movement Alert｜Veradermics, Inc. Rises 11.38% in Pre-Market Trading, Ongoing VDPHL01 Clinical Progress and Cash Position Remain in Focus
Market Focus  ·  10-20
Movement Alert｜Veradermics, Inc. Rises 11.38% in Pre-Market Trading, Ongoing VDPHL01 Clinical Progress and Cash Position Remain in Focus
Movement Alert｜Veradermics, Inc. Overnight Rise 11.38%, clinical progress and cash runway remained the core support
Market Focus  ·  10-20
Movement Alert｜Veradermics, Inc. Overnight Rise 11.38%, clinical progress and cash runway remained the core support
Veradermics Shares Rise After Positive Data for Vdphl01 Trial
Dow Jones  ·  10-19
Veradermics Shares Rise After Positive Data for Vdphl01 Trial
Movement Alert｜Veradermics, Inc. Intraday Rise 8.14% in Regular Trading, prior clinical progress and cash runway remain in focus
Market Focus  ·  10-19
Movement Alert｜Veradermics, Inc. Intraday Rise 8.14% in Regular Trading, prior clinical progress and cash runway remain in focus
Veradermics is Maintained at Buy by Needham
Dow Jones  ·  10-19
Veradermics is Maintained at Buy by Needham
Veradermics' Oral Hair-Loss Drug Shown to Boost Hair Growth in Late-Stage Study
Reuters  ·  10-19
Veradermics' Oral Hair-Loss Drug Shown to Boost Hair Growth in Late-Stage Study
Veradermics' Vdphl01 Meets All Primary and Secondary Endpoints in Phase 3 Male Hair Loss Trial
Reuters  ·  10-19
Veradermics' Vdphl01 Meets All Primary and Secondary Endpoints in Phase 3 Male Hair Loss Trial
Veradermics, Incorporated - Completes Enrollment for Female Pattern Hair Loss Trial; Topline Data Expected H1 2027
THOMSON REUTERS  ·  10-19
Veradermics, Incorporated - Completes Enrollment for Female Pattern Hair Loss Trial; Topline Data Expected H1 2027
Veradermics, Incorporated - 78.8% (Qd) and 85.0% (Bid) of Participants Reported Visible Improvement in Pro at Month 6
THOMSON REUTERS  ·  10-19
Veradermics, Incorporated - 78.8% (Qd) and 85.0% (Bid) of Participants Reported Visible Improvement in Pro at Month 6
Veradermics, Incorporated - Vdphl01 Meets All Primary and Secondary Endpoints with High Statistical Significance in Phase 3
THOMSON REUTERS  ·  10-19
Veradermics, Incorporated - Vdphl01 Meets All Primary and Secondary Endpoints with High Statistical Significance in Phase 3
Veradermics’ Oral Vdphl01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
THOMSON REUTERS  ·  10-19
Veradermics’ Oral Vdphl01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair Loss
Veradermics, Incorporated - Vdphl01 Demonstrates Favorable Safety Profile in over 1,000 Participants with no New Safety Signals
THOMSON REUTERS  ·  10-19
Veradermics, Incorporated - Vdphl01 Demonstrates Favorable Safety Profile in over 1,000 Participants with no New Safety Signals
Movement Alert｜Veradermics Rises 5.65% in Regular Trading, Positive Oral Hair Loss Drug Data and Strong Cash Position
Market Focus  ·  10-10
Movement Alert｜Veradermics Rises 5.65% in Regular Trading, Positive Oral Hair Loss Drug Data and Strong Cash Position
US Stocks on the MOVE-Palantir, Haemonetics
Reuters  ·  10-09
US Stocks on the MOVE-Palantir, Haemonetics
No data available

Introduction

Company Name.
Veradermics, Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
VeraDermics, Incorporated was founded on October 5, 2019, originally in Texas, and converted to a Delaware corporation on September 15, 2021. This late-stage clinical biopharmaceutical company, founded by dermatologists, focuses on developing innovative therapies for prevalent aesthetic and dermatological conditions. The company is primarily dedicated to addressing treatment challenges in patterned hair loss (PHL) and is advancing its lead candidate VDPHL01, an oral non-hormonal therapy designed to optimize hair growth while minimizing side effects associated with traditional treatments. VeraDermics is conducting pivotal clinical trials to support regulatory approval, aiming to transform the management of PHL through its targeted therapeutic approach.
Issue price:
--